SecBot SecBot
8-K ·Filed Aug 10, 2026

ACH

ACCENDRA HEALTH INC/VA/
BEARISH
Impact 6/10
Horizonweeks Processed2mo ago SEC0001104659-26-092999
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

Revenue and EBITDA trends remain under severe pressure from the large commercial payer exit and separation from Owens & Minor. The balance sheet restructuring (debt reduction, maturity extension) provides liquidity runway but doesn't fix the topline decline. Watch Q3/Q4 for signs of stabilization from new growth initiatives (Sleep Center of Excellence, new commercial agreements). The CEO retirement adds leadership uncertainty. With cash down to $7.7M and FCF negative, a capital raise may be needed later in 2026.

DirectionBearish
Confidencehigh
Horizonweeks
Latest settled — T+20d ⚠ clustered
ACH ▼ -21.43% at T+20d
SHORT call ✓ call won +21.43% · α vs SPY +20.51% · entry $1.40 → $1.10
Next anchor: T+60d in 7d
Latest observation: T+46 +67.99% FF3 residual α
Entry = T+0 close
Aug 10, 2026
via day close
T+1d
-10.00%
call +10.00% · α +9.68%
$1.26
settled 3mo ago
T+5d
-23.57%
call +23.57% · α +23.52%
$1.07
settled 2mo ago
T+20d
-21.43%
call +21.43% · α +20.51%
$1.10
settled 7w ago
T+60d
Pending
in 7d

Price Chart

Loading chart...

Executive Summary

Accendra Health reported Q2 2026 revenue of $613.2M (down 10.1% YoY from $681.9M) and a GAAP loss from continuing ops of $89.1M, slightly worse than last year's $83.8M loss. The company completed its balance sheet optimization (reducing total debt by $385M) and narrowed 2026 revenue guidance to $2.45-2.55B with Adj. EBITDA of $300-320M. CEO Ed Pesicka announced his retirement by end of 2026. Revenue decline from the large commercial payer exit continues to dominate results.

Key Financial Metrics

EPS
−$1.16
Revenue
$613.2M
-10.1% YoY
Rating
miss
Guidance
$2.45B-$2.55B
lowered
Free Cash Flow
-$25.1M
Gross Margin
43%

Key Facts

  • Q2 2026 net revenue $613.2M, down 10.1% YoY from $681.9M
  • GAAP loss from continuing ops $89.1M vs $83.8M in Q2 2025 (worsened)
  • Adj. EBITDA $60.1M vs $96.6M in Q2 2025 (down 37.8%)
  • Free cash flow negative $25.1M vs positive $15.2M in Q2 2025
  • Total debt reduced by $385M to $1.718B via balance sheet optimization
  • Cash dropped to $7.7M from $336.9M at March 31, 2026 (used for debt paydown)
  • CEO Ed Pesicka intends to retire by end of 2026
  • 2026 guidance revised: Revenue $2.45B-$2.55B, Adj. EBITDA $300M-$320M, FCF breakeven to slightly positive
  • Operating costs reduced by $73M YoY driven by lower SG&A and transaction breakage fee
  • Loss on modification and extinguishment of debt of $17.3M from balance sheet transaction

Financial Impact

Revenue decline of ~$68.7M YoY (-10.1%), Adj. EBITDA decline of ~$36.5M (-37.8%), GAAP net loss from continuing ops widened by ~$5.3M

revenueadjustedEBITDAfreeCashFlowdebtcash

Risk Factors

  • Ongoing revenue and EBITDA erosion from large commercial payer contract termination
  • CEO retirement creates leadership vacuum and potential strategic drift
  • Cash balance of $7.7M severely limits financial flexibility despite balance sheet restructuring
  • Free cash flow guidance only breakeven to slightly positive for full year
  • Lowered 2026 guidance vs prior implicit expectations — consensus downside risk

Market Snapshot

Exchange
NYSE
Sector
Wholesale-Medical, Dental & Hospital Equipment & Supplies
Analyst Consensus
8% bullish (12 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 7 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-092999
Document: tm2622667d2_ex99-2.htm0001104659-26-092999
Document: tm2622667d2_8k.htm0001104659-26-092999
Document: 0001104659-26-092999-index-headers.html0001104659-26-092999
Document: 0001104659-26-092999-index.html0001104659-26-092999
Document: 0001104659-26-092999.txt0001104659-26-092999
8-K Data (Synthetic)0001104659-26-092999
15 reports for ACH
Performance horizon
100% Hit rate @ T+5 5 of 5 directional calls Went positive at some point 5 of 5 best @ T+60▲ +62.31%Jun 11, 2026
Filters
Rows
Reports for ACH — sortable, filterable
TypeNow
Oct 9, 2026
17d ago
8-K
BEARISH ★ 7/10
$0.3905 $0.2202▲ +43.61%▲ +42.12%$0.2069 (+47.02%)
Oct 7, 2026
20d ago
SC 13G
NEUTRAL ★ 4/10
$0.4729 $0.3128▼ −33.85%▼ −32.87%$0.2069 (−56.25%)
Sep 17, 2026
5w ago
8-K
NEUTRAL ★ 3/10
$1.03 $0.7332▼ −28.82%▼ −29.42%$0.2069 (−79.91%)
Aug 17, 2026
10w ago
8-K
BULLISH ★ 5/10
$1.07 $1.16▲ +8.41%▲ +9.60%$0.2069 (−80.66%)
Aug 16, 2026
10w ago
Institutional Cluster
MIXED ★ 5/10
$1.07 $1.16▲ +8.41%▲ +9.60%$0.2069 (−80.66%)
Aug 10, 2026
11w ago
8-K
NEUTRAL ★ 4/10
$1.26 $1.13▼ −10.32%▼ −9.91%$0.2069 (−83.58%)
Aug 10, 2026
11w ago
8-K
BEARISH ★ 6/10
$1.40 $1.07▲ +23.57%▲ +23.52%$0.2069 (+85.22%)
Aug 10, 2026
11w ago
8-K
NEUTRAL ★ 3/10
$1.40 $1.07▼ −23.57%▼ −23.52%$0.2069 (−85.22%)
Jul 27, 2026
13w ago
EFFECT
NEUTRAL ★ 3/10
$3.22 $3.41▲ +5.90%▲ +3.39%$0.2069 (−93.57%)
Jun 25, 2026
17w ago
8-K
NEUTRAL ★ 5/10
$3.34 $3.59▲ +7.49%▲ +5.32%$0.2069 (−93.81%)
Showing 10 of 15

US Market Status

Market Closed — Opens Wed (17h 23m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026